jueves, 10 de abril de 2014

NCTR Publications > NCTR Research Highlights

NCTR Publications > NCTR Research Highlights

National Center for Toxicological Researh log with FDA on left side

NCTR Research Highlights

Current Highlight from April 4, 2014

Component of Green Tea Inhibits Mitochondrial Respiratory Complexes
Scientists from NCTR, the University of Arkansas for Medical Sciences, and PharmPoint Consulting have shown that epigallocatechin gallate (EGCG) binds to and inhibits respiratory chain complexes in swollen, but not normal, mitochondria isolated from rat liver.  Swollen mitochondria are more permeable due to compromised integrity of the inner membrane.  EGCG is an abundant flavonoid in green tea and is also consumed in dietary supplements for weight loss and as a cancer prevention; however, EGCG has also been associated with hepatotoxicity through unknown mechanisms.  This study suggests that EGCG may trigger hepatotoxicity by worsening pre-existing mitochondrial abnormalities.  This work was published inBiochemical and Biophysical Research Communicationsdisclaimer icon (2014, 443: 1097-1104).
For additional information, please contact Qiang Shi, Ph.D., Division of Systems Biology, FDA/NCTR.
Arkansas Nanotechnology for Health Care Conference
NCTR scientists presented their research at the annual Arkansas Nanotechnology for Health Care Conference held April 2-4, 2014 at the Winthrop Rockefeller Institute.  The NCTR presentation topics included iron oxide nanoparticle-induced neurotoxicity and evaluation of genotoxicity of nanomaterials.  Other topics covered during the conference in relation to nanotechnology and health care included:
  • development and testing of nanoplatforms/nanomedicines in in vitro and in vivo models of cancer and other diseases
  • use of nanomaterials for in vitro diagnostics
  • detection of nanoplatforms/nanodrugs in in vivo systems
The goals of this conference are to communicate the latest information on nanotechnology and health care through presentations from local, national, and international experts (including FDA and other government agencies), and to foster collaborations among state institutions and national partners. 
For additional information, please contact Paul Howard, Ph.D., Director, Office of Scientific Coordination, FDA/NCTR.

No hay comentarios:

Publicar un comentario